ArticleTheranostics2022
Hydroxyurea ameliorates atherosclerosis in ApoE
Open access · goldAbstract read
In one paragraph
Article in Theranostics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
3.7field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- Gut microbiota regulate atherosclerosis via the gut-vascular axis: a scoping review of mechanisms and therapeutic interventions.Frontiers in microbiology · 2025Pooled it
- Elovl6 inhibits colorectal cancer progression through stearic acid-mediated mitochondrial fusion and metabolic reprogramming.Science advances · 2026Article
- Beyond conventional therapies: Gut microbiota modulation and macromolecular drugs in the battle against cardiometabolic diseases.Journal of pharmaceutical analysis · 2026Review
- EFHD1: A Potential Prognostic Biomarker Related to Mitochondrial Function and Aging in Atherosclerosis Plaque.Current medicinal chemistry · 2026Article
- Engineered endothelial cells targeting and dihydrotanshinone I loaded bacterial extracellular vesicles for atherosclerosis therapy.Bioengineering & translational medicine · 2025Article
- Are an Aging Gut and a Decrease in Butyrate Production the Reasons for Atherosclerosis?International journal of molecular sciences · 2025Review
- Gut microbiota: a novel strategy affecting atherosclerosis.Microbiology spectrum · 2025Review
- Mechanisms of exercise in preventing cardiovascular diseases: Insights from gut microbiota characteristics in pathological states of cardiovascular diseases.Reviews in endocrine & metabolic disorders · 2025Review
- Biomimetic nanocomplexes loading with evolocumab and curcumin for synergistic anti-atherosclerosis therapy in ApoEJournal of nanobiotechnology · 2025Article
- Omics research in atherosclerosis.Molecular and cellular biochemistry · 2025Review
- Effects of microplastics on chemo-resistance and tumorigenesis of colorectal cancer.Apoptosis : an international journal on programmed cell death · 2025Article
- A New Insight on Atherosclerosis Mechanism and Lipid-Lowering Drugs.Reviews in cardiovascular medicine · 2025Review
- Systemic lupus erythematosus and atherosclerosis: immune pathways and the uncharted territory of gut microbiota and metabolism.Frontiers in immunology · 2025Review
- Article
- Functionalized Periodic Mesoporous Silica Nanoparticles for Inhibiting the Progression of Atherosclerosis by Targeting Low-Density Lipoprotein Cholesterol.Pharmaceutics · 2024Article
- Revitalizing myocarditis treatment through gut microbiota modulation: unveiling a promising therapeutic avenue.Frontiers in cellular and infection microbiology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 3 institutions in 1 country.
Xin-Yu YangThe First Hospital of Jilin University, Changchun, 130021, China.
Hang YuState Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences/Peking Union Medical College, Beijing 100050, China.
Jie FuState Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences/Peking Union Medical College, Beijing 100050, China.
Hui-Hui GuoState Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences/Peking Union Medical College, Beijing 100050, China.
Pei HanState Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences/Peking Union Medical College, Beijing 100050, China.
Shu-Rong MaState Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences/Peking Union Medical College, Beijing 100050, China.
Li-Bin PanState Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences/Peking Union Medical College, Beijing 100050, China.
Zheng-Wei ZhangState Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences/Peking Union Medical College, Beijing 100050, China.
Hui XuState Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences/Peking Union Medical College, Beijing 100050, China.
Jia-Chun HuState Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences/Peking Union Medical College, Beijing 100050, China.
Hao-Jian ZhangState Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences/Peking Union Medical College, Beijing 100050, China.
Meng-Meng BuState Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences/Peking Union Medical College, Beijing 100050, China.
Xian-Feng ZhangThe First Hospital of Jilin University, Changchun, 130021, China.
Wei YangThe First Hospital of Jilin University, Changchun, 130021, China.
Jing-Yue WangThe First Hospital of Jilin University, Changchun, 130021, China.
Jing-Yu JinThe First Hospital of Jilin University, Changchun, 130021, China.
Hui-Cong ZhangThe First Hospital of Jilin University, Changchun, 130021, China.
Dong-Rui LiThe First Hospital of Jilin University, Changchun, 130021, China.
Jin-Yue LuState Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences/Peking Union Medical College, Beijing 100050, China.
Yuan LinState Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences/Peking Union Medical College, Beijing 100050, China.
Jian-Dong JiangState Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences/Peking Union Medical College, Beijing 100050, China.
Qian TongThe First Hospital of Jilin University, Changchun, 130021, China.
Yan WangState Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences/Peking Union Medical College, Beijing 100050, China.
Chinese Academy of Medical Sciences & Peking Union Medical College · CNJilin University · CNFirst Hospital of Jilin University · CN
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
AtherosclerosisGastrointestinal MicrobiomeAnimalsApolipoproteins EAzo CompoundsHydroxyureaMiceNiemann-Pick C1 ProteinRNA, Ribosomal, 16SApolipoproteins EAzo CompoundsHydroxyureaNiemann-Pick C1 Proteinoil red ORNA, Ribosomal, 16SAtherosclerosisGut microbiotaHydroxyureaLipid metabolismNPC1L1
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.